Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient

Annals of Thoracic Surgery

Volumn 79, Issue 3, 2005, Pages 1081-1089

  Lazar, Harold L ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMLODIPINE; BENAZEPRIL; BENAZEPRILAT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; LISINOPRIL; LOSARTAN; MOEXIPRIL; PERINDOPRILAT; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINAPRIL; QUINAPRILAT; RAMIPRIL; RAMIPRILAT; SIMVASTATIN; TRANDOLAPRIL;

ANGIONEUROTIC EDEMA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TISSUE LEVEL; DRUG TOLERANCE; ENZYME INHIBITION; FIBRINOLYSIS; FOOD AND DRUG ADMINISTRATION; GRAFT PATENCY; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATATION;

EID: 14244263806     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2004.05.046     Document Type: Review

References (61)

1. M.A. Pfeffer, E. Braunwald, L.A. Moye Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the Survival and Ventricular Enlargement Trial N Engl J Med 327 1992 669 677
2. The Studies on Left Ventricular Dysfunction (SOLVD) Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
3. G.B. Mancini, G.C. Henry, C. Macaya Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary disease the Trial on Reversing Endothelial Dysfunction (TREND) study Circulation 94 1996 258 265
4. T.J. Anderson, E. Elstein, H. Haber, F. Charbonneau Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF) study J Am Coll Cardiol 35 2000 60 66
5. V.J. Dzau Tissue angiotensin and pathobiology of vascular disease a unifying hypothesis Hypertension 37 2001 1047 1052
6. M.K. O'Donohoe, L.B. Schwartz, Z.S. Radic Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts Ann Surg 214 1991 727 731
7. J.E. Fabre, A. Rivard, M. Magner, M. Silver, J.M. Isner Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo Circ 99 1999 3043 3049
8. W. Linz, G. Wiemer, P. Gohlke, T. Unger, B.A. Scholkens Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors Pharmacol Rev 47 1995 25 49
9. S. Rajagopalan, S. Kurz, T. Munzel Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation contribution to alterations of vasomotor tone J Clin Invest 97 1996 1916 1923
10. H. Morawietz, U. Rueckschloss, B. Niemann Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein Circulation 100 1999 899 902
11. S. Hoshida, J. Kato, M. Nishino Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome Circulation 103 2001 630 633
12. M.R. Weir, J.V. Dzau The renin-angiotensin-aldosterone system a specific target for hypertension management Am J Hypertens 12 1999 205S 213S
13. W. Hamsten, G. Wiman, U. De Faire, M. Blomback Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor activity in young survivors of myocardial infarction N Engl J Med 313 1985 1557 1563
14. H. Scherf, R. Pietsch, G. Landsberg, H.J. Kramer, R. Dusing Converting enzyme inhibitor ramipril stimulates prostacylin synthesis by isolated rat aorta evidence for a kinin-dependent machanism Klin. Wochenschr 64 1986 742 745
15. D. Grimm, E.P. Kromer, W. Brocker Regulation of extracellular matrix proteins in pressure-overload cardiac hypentrophy effects of angiotensin-converting enzyme inhibition J Hypertens 16 1998 1345 1355
16. A. Penzio, J. Pando, M. Hernandez, M.F. Galindo, E. Cenarruzabeitia, J. Diez Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats Am J Hypertens 8 1995 815 822
17. N.J. Brown, M.A. Agirbajli, G.H. Williams, W.R. Litchfield, D.E. Vaughan Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 Hypertension 32 1998 965 971
18. M. Takemoto, K. Egashira, M. Usui Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats J Clin Invest 99 1997 278 287
19. V.J. Dzau Tissue renin-angiotensin system in myocardial hypertrophy Arch Intern Med 153 1993 937 942
20. T. Unger, D. Ganten, R.E. Lang Effect of converting enzyme inhibitors on tissue converting enzyme and angiotensin II therapeutic implications Am J Cardiol 59 1987 18D 22D
21. B. Fabris, B.Z. Chen, V. Pupic, R. Perich, C.I. Johnston Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue J Cardiovasc Pharmacol 15 1990 56-63
22. M. Miyazaki, H. Sakonjo, S. Takai Anti-atherosclerotic effects of an angiotensin-converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet Br J Pharmacol 128 3 1999 523 529
23. D.D. Potter, C.G. Sobey, P.K. Tompkins, J.D. Rosien, D.D. Heistad Evidence that macrophages in atherosclerotic lesions contain angiotensin II Circ 98 1998 800 807
24. F. Diet, R.E. Pratt, G.J. Berry, N. Momose, G.H. Gibbons, V.J. Dzau Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease Circ 94 1996 2756 2767
25. J.A.A. Borlan, A.H. Chester, S. Crabbe, J.B. Parkerson, J.D. Catravas, M.H. Yacoub Differential action of angiotensin II and activity of angiotensin-convertising enzyme in human bypass grafts J Thorac Cardiovasc Surg 116 1998 206 212
26. M.B. Britten, A.M. Zeiher, V. Schachinger Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options J Intern Med 245 1999 315 327
27. H. Drexler, B. Hornig Endothelial dysfunction in human disease J Mol Cell Cardiol 31 1999 51 60
28. T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, T. Munzel Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease Circulation 104 2001 2673 2678
29. B. Hornig, N. Arakawa, D. Haussmann, H. Drexler Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure Circ 98 1998 2842 2848
30. K. Swedberg, P. Held, J. Kjekshus, K. Rasmussen, L. Ryden, H. Wedel the Cooperative New Scandinavian Enalapril Survival Study (CONSENSUS) II Study Group Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med 327 1992 678 684
31. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 342 1993 821 828
32. L. Kober, C. Topr-Pedersen, J.E. Carlsen A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 333 1995 1670 1676
33. M.A. Pfeffer, S.C. Greaves, J.M. Arnold Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy (HEART) Trial Circulation 95 1997 2643 2651
34. ACE Inhibitor Myocardial Infarction Collaborative Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction systematic overview of individual data from 100,000 patients in randomized trials Circulation 97; 1998 2202 2212
35. D.E. Vaughan, J.L. Rouleau, P.M. Ridker, M.O. Arnold, F.J. Menapace, M.A. Pfeffer the Healing and Early Afterload Reducing Therapy (HEART) study investigators Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction Circulation 96 1997 442 447
36. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
37. W.M. Lonn, S. Yusuf, C.I. Doris Study design and baseline characteristics of the Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) Am J Cardiol 8 1996 914 919
38. K. Hosomi, K. Mizushige, H. Ohyama, Y. Hatanaka, H. Matsuo, J. Koziol ACE inhibition with enelapril slows progressive intima-media thickening of common carotid artery in NIDDM patients [abstract] Circulation 102 Suppl II 2000 II-869
39. J.C. Hartman The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors Ann Thorac Surg 60 1995 789 792
40. J. Gurevitch, D. Pevni, T. Frolkis Captopril in cardioplegia and reperfusion protective effects on the ischemic heart Ann Thorac Surg 63 1997 627 633
41. N.M. Engelman, J.A. Rousou, J. Iyengar, D.K. Das Captopril, an ACE inhibitor, for optimizing reperfusion after acute myocardial infarction Ann Thorac Surg 52 1991 918 926
42. N. Hayashida, S. Chihara, E. Tayama Effects of angiotensin-converting enzyme inhibitor during warm blood cardioplegia Ann Thorac Surg 70 2000 627 632
43. S. Fischer, A.A. MacLean, M. Liu, B. Kalirai, S. Keshavjee Inhibition of angiotensin-converting enzyme by captopril a novel approach to reduce ischemia-reperfusion injury after lung transplantation J Thorac Cardiovasc Surg 120 2000 573 580
44. H.L. Lazar, Y. Bao, S. Rivers, T. Colton, S.A. Bernard High tissue affinity angiotensin-converting enzyme inhibitors improve endothelial function and reduce infarct size Ann Thorac Surg 72 2001 548 554
45. B. Hornig, C. Kohler, H. Drexler Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans Circ 95 1997 1115 1118
46. S. Hoshida, N. Yamashita, K. Kawahara, T. Kuzuya, M. Hori Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis Circ 99 1999 434 440
47. H.L. Lazar, Y. Bao, S. Rivers, S. Bernard Pretreatment with angiotensin-converting inhibitors attenuates ischemic reperfusion injury during coronary revascularization Ann Thorac Surg 73 2002 1522 1527
48. M. Oosterga, A.A. Voors, V.M. Pinto Effects of quinapril on clinical outcome after coronary bypass grafting (the QUOVADIS study) J Am Coll Cardiol 87 2001 542 546
49. L. Knoller-Hansen, R. Steffesnsen, P. Grande The Angiotensin-converting Enzyme Inhibition Post-Revascularization Study (APRES) J Am Coll Cardiol 35 2000 8881 8888
50. S. Sirivella, I. Gielchinsky, V. Parsonnet Angiotensin-converting enzyme inhibitor therapy in severe postcardiotomy dysfunction a prospective randomized study J Cardiac Surg 13 1998 11 17
51. H.G. Predel, Z. Yang, L. von Segesser Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle Lance 340 1992 878 882
52. J.E. Bishop, L.A. Kirnan, R.P. Butt Mechanical load enhances the stimulating effect of angiotensin II on human cardiac fibroblast procollagen synthesis Circ 94 1996 1657 1661
53. F. Ribichini, F. Pugno, V. Ferrero Angiotensin-converting enzyme tissue activity in the diffuse in-stent restenotic plaque Circ 101 2000 33 35
54. T. Okimoto, M. Imazu, Y. Hayaghi Quinapril with high affinity to tissue angiotensin-converting enzyme inhibitor reduces restenosis after percuteneous transcatheter coronary revascularization J Am Coll Cardiol 35 2000 37A
55. J.H. O'Keefe, M. Wetzel, R.R. Moe, K. Brosnahan, C.H. Lavie Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol 37 2001 1 8
56. M. Pretorius, L.J. Murphey, J.A. McFarlane, D.E. Vaughan, N.J. Brown Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass Circ 108 2003 3079 3083
57. W.J. Waugh Factors to consider in selecting an angiotensin-converting enzyme inhibitor Am J Health-Syst Ph 57 Suppl I 2000 S26 S30
58. J.E. Henney From the Food and Drug Administration preventive use for ramipril JAMA 248 2000 2711
59. C.D. Deakin, M.J.R. Dalrymple-Hay, P. Jones, J.L. Monro Effects of angiotensin-converting enzyme inhibition on systemic vascular resistance and vasoconstrictor requirements during hypothemic cardiopulmonary bypass Euro J Cardiothoracic Surg 26 2003 387 391
60. A.P. Maggione, R. Latini How to use ACE inhibitors, beta-blockers, and new therapies in AMI Am Heart J 138 1999 183 187
61. B. Yusef Two decades of progress in preventing vascular disease Lancet 360 2002 2 3